Sueki Hirohiko, Sugiyama Seiko, Aoyama Yumi, Yamamoto Takenobu, Watanabe Hideaki, Inomata Naoko, Kubota Yutaro, Horiike Atsushi, Tsunoda Takuya, Tanaka Toru, Watanabe Yuko, Yamaguchi Yukie, Mizukawa Yoshiko, Kato Yukihiko, Hama Natsumi, Abe Riichiro, Noguchi Kazuteru, Matsui Kiyoshi, Niihara Hiroyuki, Otsuki Takemi, Shimizu Yurika, Ito Tatsuo, Inoue Eisuke, Kubota Kaoru
Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
Department of Dermatology, Kawasaki Medical School, Okayama, Japan.
J Dermatol. 2025 Jun;52(6):1015-1030. doi: 10.1111/1346-8138.17706. Epub 2025 Mar 29.
The concept of immune reconstitution inflammatory syndrome (IRIS) has recently been applied to patients with non-HIV infection with immune fluctuations. However, quantitative criteria to diagnose non-HIV IRIS have not been established. Similarly, immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) are also caused by immune fluctuations. No study has directly compared the immunological indicators of non-HIV IRIS and irAEs. Thus, we investigated whether irAEs can be included in non-HIV IRIS. We aimed to search for diagnostic biomarkers for non-HIV IRIS and to compare the immunopathogenesis of non-HIV IRIS and irAEs based on immunological indicators. We selected drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid (DPP4i-BP) as underlying diseases of non-HIV IRIS. Blood cell counts, cytokines or chemokines, and herpesvirus-derived DNA in saliva were quantified and compared between IRIS/irAE-positive and -negative as well as non-HIV IRIS and irAEs groups. The DPP4i-BP group had a shorter incubation time to IRIS onset than the DIHS/DRESS group; the irAE group had a longer incubation time than the DIHS/DRESS group. A higher neutrophil-to-lymphocyte ratio and serum interferon gamma inducible protein 10 levels could be potential biomarkers of IRIS and irAEs onset; however, no useful cut-off values for diagnosis were indicated. Meanwhile, the transition of regulatory T cells (Tregs) from the baseline to the onset of IRIS or irAEs differed between IRIS in DIHS/DRESS and irAEs. Only the DIHS/DRESS group showed an increase of Epstein-Bar virus (EBV) (p < 0.0001) and human herpesvirus 6 (p < 0.05) positivity in saliva at the onset of IRIS compared to that at baseline. Although non-HIV IRIS and irAEs have a small number of common immunological indicators, the dynamics of Tregs, cytokines, or chemokines and positivity of herpesvirus-derived DNA in saliva differ, suggesting that non-HIV IRIS and irAEs should remain as separate entities.
免疫重建炎症综合征(IRIS)的概念最近已应用于伴有免疫波动的非HIV感染患者。然而,诊断非HIV IRIS的定量标准尚未确立。同样,免疫检查点抑制剂(ICI)引起的免疫相关不良事件(irAE)也是由免疫波动所致。尚无研究直接比较非HIV IRIS和irAE的免疫指标。因此,我们研究了irAE是否可纳入非HIV IRIS。我们旨在寻找非HIV IRIS的诊断生物标志物,并基于免疫指标比较非HIV IRIS和irAE的免疫发病机制。我们选择药物性超敏反应综合征/伴嗜酸性粒细胞增多和全身症状的药物反应(DIHS/DRESS)以及二肽基肽酶-4抑制剂相关大疱性类天疱疮(DPP4i-BP)作为非HIV IRIS的基础疾病。对IRIS/irAE阳性和阴性以及非HIV IRIS和irAE组的血细胞计数、细胞因子或趋化因子以及唾液中疱疹病毒衍生的DNA进行定量和比较。DPP4i-BP组至IRIS发病的潜伏期短于DIHS/DRESS组;irAE组的潜伏期长于DIHS/DRESS组。较高的中性粒细胞与淋巴细胞比率和血清干扰素γ诱导蛋白10水平可能是IRIS和irAE发病的潜在生物标志物;然而,未表明有诊断的有用临界值。同时,DIHS/DRESS中的IRIS和irAE之间,从基线到IRIS或irAE发病时调节性T细胞(Treg)的转变有所不同。仅DIHS/DRESS组在IRIS发病时唾液中EB病毒(EBV)(p<0.0001)和人疱疹病毒6(p<0.05)阳性率较基线时增加。尽管非HIV IRIS和irAE有少量共同的免疫指标,但Treg、细胞因子或趋化因子的动态变化以及唾液中疱疹病毒衍生DNA的阳性率不同,这表明非HIV IRIS和irAE应仍作为独立的实体。